- Home
- TSHA vs SPFI Comparison
TSHA vs SPFI Comparison
Compare TSHA & SPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- SPFI
- Stock Information
- Founded
- TSHA 2019
- SPFI 1941
- Country
- TSHA United States
- SPFI United States
- Employees
- TSHA N/A
- SPFI N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- SPFI Major Banks
- Sector
- TSHA Health Care
- SPFI Finance
- Exchange
- TSHA Nasdaq
- SPFI Nasdaq
- Market Cap
- TSHA 728.4M
- SPFI 662.8M
- IPO Year
- TSHA 2020
- SPFI 2019
- Fundamental
- Price
- TSHA $3.02
- SPFI $40.33
- Analyst Decision
- TSHA Strong Buy
- SPFI Buy
- Analyst Count
- TSHA 7
- SPFI 3
- Target Price
- TSHA $8.71
- SPFI $41.67
- AVG Volume (30 Days)
- TSHA 3.5M
- SPFI 47.5K
- Earning Date
- TSHA 11-12-2025
- SPFI 10-22-2025
- Dividend Yield
- TSHA N/A
- SPFI 1.51%
- EPS Growth
- TSHA N/A
- SPFI 19.09
- EPS
- TSHA N/A
- SPFI 3.20
- Revenue
- TSHA $8,098,000.00
- SPFI $199,001,000.00
- Revenue This Year
- TSHA N/A
- SPFI $13.41
- Revenue Next Year
- TSHA N/A
- SPFI $6.10
- P/E Ratio
- TSHA N/A
- SPFI $12.44
- Revenue Growth
- TSHA N/A
- SPFI 7.49
- 52 Week Low
- TSHA $1.05
- SPFI $30.01
- 52 Week High
- TSHA $3.40
- SPFI $42.38
- Technical
- Relative Strength Index (RSI)
- TSHA 51.14
- SPFI 54.27
- Support Level
- TSHA $3.16
- SPFI $39.40
- Resistance Level
- TSHA $2.99
- SPFI $40.93
- Average True Range (ATR)
- TSHA 0.18
- SPFI 0.98
- MACD
- TSHA -0.01
- SPFI -0.16
- Stochastic Oscillator
- TSHA 38.21
- SPFI 37.05
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.